138 related articles for article (PubMed ID: 38568057)
1. Development, synthesis and validation of improved c-Myc/Max inhibitors.
Yıldırım S; Kocabaş F; Mermer A
J Cell Mol Med; 2024 Apr; 28(8):e18272. PubMed ID: 38568057
[TBL] [Abstract][Full Text] [Related]
2. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
3. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
4. Discovery of methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization.
Chauhan J; Wang H; Yap JL; Sabato PE; Hu A; Prochownik EV; Fletcher S
ChemMedChem; 2014 Oct; 9(10):2274-2285. PubMed ID: 24976143
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (Type II).
Yılmaz Ö; Bayer B; Bekçi H; Uba AI; Cumaoğlu A; Yelekçi K; Küçükgüzel ŞG
Med Chem; 2020; 16(6):735-749. PubMed ID: 31203805
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.
Olgen S; Biltekin Kaleli SN; Karaca BT; Demirel UU; Bristow HK
Curr Med Chem; 2023 Jun; ():. PubMed ID: 37365789
[TBL] [Abstract][Full Text] [Related]
7. 3JC48-3 (methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth.
Shukla S; Fletcher S; Chauhan J; Chalfant V; Riveros C; Mackeyev Y; Singh PK; Krishnan S; Osumi T; Balaji KC
Cancer Gene Ther; 2022 Nov; 29(11):1550-1557. PubMed ID: 35440696
[TBL] [Abstract][Full Text] [Related]
8. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.
Shah CP; Kharkar PS
Eur J Med Chem; 2018 Oct; 158():286-301. PubMed ID: 30223117
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors modulate anticancer and anti-proliferative properties via NF-kB signaling, and ubiquitin-proteasome pathways in cancer cell lines of different organs.
Qureshi AA; Zuvanich EG; Khan DA; Mushtaq S; Silswal N; Qureshi N
Lipids Health Dis; 2018 Apr; 17(1):62. PubMed ID: 29606130
[TBL] [Abstract][Full Text] [Related]
11. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Foo J; Singh K; Lee J; Kalyta A; Morin H; Perez C; Ban F; Leblanc E; Lallous N; Cherkasov A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269731
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract][Full Text] [Related]
13. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
14. Lipid phosphate phosphatase-2 promotes tumor growth through increased c-Myc expression.
Tang X; Cromwell CR; Liu R; Godbout R; Hubbard BP; McMullen TPW; Brindley DN
Theranostics; 2022; 12(13):5675-5690. PubMed ID: 35966578
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest.
Jeong KC; Ahn KO; Yang CH
Mol Biosyst; 2010 Aug; 6(8):1503-9. PubMed ID: 20485733
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
17. Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.
Jung KY; Wang H; Teriete P; Yap JL; Chen L; Lanning ME; Hu A; Lambert LJ; Holien T; Sundan A; Cosford ND; Prochownik EV; Fletcher S
J Med Chem; 2015 Apr; 58(7):3002-24. PubMed ID: 25734936
[TBL] [Abstract][Full Text] [Related]
18. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E
APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138
[TBL] [Abstract][Full Text] [Related]
19. Novel Primary Human Cancer Stem-Like Cell Populations from Non-Small Cell Lung Cancer: Inhibition of Cell Survival by Targeting NF-κB and MYC Signaling.
Windmöller BA; Beshay M; Helweg LP; Flottmann C; Beermann M; Förster C; Wilkens L; Greiner JFW; Kaltschmidt C; Kaltschmidt B
Cells; 2021 Apr; 10(5):. PubMed ID: 33925297
[TBL] [Abstract][Full Text] [Related]
20.
Hallaq T; Al-Hiari Y; Kasabri V; AlBashiti R; AlAlawi S; Telfah A
Anticancer Agents Med Chem; 2022; 22(19):3304-3321. PubMed ID: 35570520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
